MYGN

SEC source: 0001770252-21-000011 · edgardoc.xml · nonDerivative · entry 3

Lambert Nicole · CIK 0001770252 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 178,072

F2 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.43 to $33.62, inclusive. The Reporting Person undertakes to provide to Myriad Genetics, Inc., any security holder of Myriad Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001770252-21-000011 · edgardoc.xml · nonDerivative · entry 2

Lambert Nicole · CIK 0001770252 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 188,184

F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on September 24, 2021.

SEC source: 0001517026-21-000007 · edgardoc.xml · nonDerivative · entry 2

Verratti Mark · CIK 0001517026 · President, Myriad Neuroscience

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 202,359

F2 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of performance-based restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on September 24, 2021.

SEC source: 0001843872-21-000013 · edgardoc.xml · nonDerivative · entry 2

Haas Kevin Richard · CIK 0001843872 · Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 54,902

F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on September 24, 2021.

SEC source: 0001519749-21-000015 · edgardoc.xml · nonDerivative · entry 2

Hart Jayne B. · CIK 0001519749 · Chief People Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 110,120

F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on September 24, 2021.

SEC source: 0001219036-21-000029 · edgardoc.xml · nonDerivative · entry 3

LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 275,135

F2 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of performance-based restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on September 24, 2021.

SEC source: 0001621899-21-000011 · edgardoc.xml · nonDerivative · entry 2

Riggsbee Richard Bryan · CIK 0001621899 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 369,163

F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of performance-based restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on September 24, 2021.

SEC source: 0001770252-21-000011 · edgardoc.xml · nonDerivative · entry 1

Lambert Nicole · CIK 0001770252 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 191,610

F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on September 24, 2021.

SEC source: 0001517026-21-000007 · edgardoc.xml · nonDerivative · entry 1

Verratti Mark · CIK 0001517026 · President, Myriad Neuroscience

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 205,873

F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on September 24, 2021.

SEC source: 0001843872-21-000013 · edgardoc.xml · nonDerivative · entry 1

Haas Kevin Richard · CIK 0001843872 · Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,767

F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on September 24, 2021.

SEC source: 0001519749-21-000015 · edgardoc.xml · nonDerivative · entry 1

Hart Jayne B. · CIK 0001519749 · Chief People Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 112,336

F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on September 24, 2021.

SEC source: 0001219036-21-000029 · edgardoc.xml · nonDerivative · entry 2

LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 278,768

F2 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of performance-based restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on September 24, 2021.

SEC source: 0001621899-21-000011 · edgardoc.xml · nonDerivative · entry 1

Riggsbee Richard Bryan · CIK 0001621899 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 373,704

F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of performance-based restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on September 24, 2021.

SEC source: 0001219036-21-000029 · edgardoc.xml · nonDerivative · entry 1

LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 288,515

F1 · kind: The transaction reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan.

SEC source: 0000899243-21-037886 · doc4.xml · nonDerivative · entry 2

DIAZ PAUL J · CIK 0001194247 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 796,098

F2 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of performance-based restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on September 23, 2021.

SEC source: 0000899243-21-037886 · doc4.xml · nonDerivative · entry 1

DIAZ PAUL J · CIK 0001194247 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 845,488

F1 · kind: Consists of performance-based restricted stock units (PSUs) initially granted on October 8, 2020, subject to accomplishment of pre-determined performance metrics. On September 23, 2021, the Board of Directors determined the final award amount based on the accomplishment of the applicable performance metrics. Each PSU represents a contingent right to receive one share of the Company's common stock, and vests 25% on September 23, 2021, and the remaining seventy-five percent (75%) of the earned PSUs will vest in three (3) installments of 25% each on the following dates: August 13, 2022, August 13, 2023, and August 13, 2024.

SEC source: 0001519749-21-000013 · edgardoc.xml · nonDerivative · entry 1

Hart Jayne B. · CIK 0001519749 · Chief People Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 116,214

F1 · kind: Consists of performance-based restricted stock units (PSUs) granted pursuant to the Company's 2017 Employee, Director and Consultant Equity Incentive Plan. The PSUs were initially granted on October 8, 2020, subject to accomplishment of pre-determined performance metrics. On September 21, 2021, the Compensation and Human Capital Committee determined the final award amount based on the accomplishment of the applicable performance metrics. Each PSU represents a contingent right to receive one share of the Company's common stock, and vests 25% on October 9, 2021, 25% on October 9, 2022, 25% on October 9, 2023, and 25% on October 9, 2024.

SEC source: 0001770252-21-000009 · edgardoc.xml · nonDerivative · entry 1

Lambert Nicole · CIK 0001770252 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 192,921

F1 · kind: Consists of performance-based restricted stock units (PSUs) granted pursuant to the Company's 2017 Employee, Director and Consultant Equity Incentive Plan. The PSUs were initially granted on October 8, 2020, subject to accomplishment of pre-determined performance metrics. On September 21, 2021, the Compensation and Human Capital Committee determined the final award amount based on the accomplishment of the applicable performance metrics. Each PSU represents a contingent right to receive one share of the Company's common stock, and vests 25% on October 9, 2021, 25% on October 9, 2022, 25% on October 9, 2023, and 25% on October 9, 2024.

SEC source: 0001517026-21-000005 · edgardoc.xml · nonDerivative · entry 2

Verratti Mark · CIK 0001517026 · President, Myriad Neuroscience

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 212,619

F2 · kind: Consists of performance-based restricted stock units (PSUs) granted pursuant to the Company's 2017 Employee, Director and Consultant Equity Incentive Plan. The PSUs were initially granted on October 8, 2020, subject to accomplishment of pre-determined performance metrics. On September 21, 2021, the Compensation and Human Capital Committee determined the final award amount based on the accomplishment of the applicable performance metrics. Each PSU represents a contingent right to receive one share of the Company's common stock, and vests 25% on October 9, 2021, 25% on October 9, 2022, 25% on October 9, 2023, and 25% on October 9, 2024.

SEC source: 0001517026-21-000005 · edgardoc.xml · nonDerivative · entry 1

Verratti Mark · CIK 0001517026 · President, Myriad Neuroscience

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 166,048

F1 · kind: Consists of time-based restricted stock units granted pursuant to the Company's 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock and vests in four equal annual installments beginning on the first anniversary of the grant date.

SEC source: 0001219036-21-000027 · edgardoc.xml · nonDerivative · entry 1

LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 288,715

F1 · kind: Consists of performance-based restricted stock units (PSUs) granted pursuant to the Company's 2017 Employee, Director and Consultant Equity Incentive Plan. The PSUs were initially granted on October 8, 2020, subject to accomplishment of pre-determined performance metrics. On September 21, 2021, the Compensation and Human Capital Committee determined the final award amount based on the accomplishment of the applicable performance metrics. Each PSU represents a contingent right to receive one share of the Company's common stock, and vests 25% on October 9, 2021, 25% on October 9, 2022, 25% on October 9, 2023, and 25% on October 9, 2024.

SEC source: 0001621899-21-000009 · edgardoc.xml · nonDerivative · entry 1

Riggsbee Richard Bryan · CIK 0001621899 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 385,611

F1 · kind: Consists of performance-based restricted stock units (PSUs) granted pursuant to the Company's 2017 Employee, Director and Consultant Equity Incentive Plan. The PSUs were initially granted on October 8, 2020, subject to accomplishment of pre-determined performance metrics. On September 21, 2021, the Compensation and Human Capital Committee determined the final award amount based on the accomplishment of the applicable performance metrics. Each PSU represents a contingent right to receive one share of the Company's common stock, and vests 25% on October 9, 2021, 25% on October 9, 2022, 25% on October 9, 2023, and 25% on October 9, 2024.

SEC source: 0001519749-21-000011 · edgardoc.xml · derivative · entry 6

Hart Jayne B. · CIK 0001519749 · Chief People Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 73,225 shares

Expires 2021-09-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable.

SEC source: 0001519749-21-000011 · edgardoc.xml · derivative · entry 5

Hart Jayne B. · CIK 0001519749 · Chief People Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,775 shares

Expires 2021-09-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable.

SEC source: 0001519749-21-000011 · edgardoc.xml · nonDerivative · entry 4

Hart Jayne B. · CIK 0001519749 · Chief People Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 89,616

F2 · kind: Represents the net exercise of outstanding stock options. The reporting person received 809 shares of common stock on net exercise of options to purchase 3,775 shares of common stock. The company withheld 2,966 shares of common stock for payment of the exercise price and tax withholdings, using the closing stock price on September 17, 2021 of $33.72.

SEC source: 0001519749-21-000011 · edgardoc.xml · nonDerivative · entry 3

Hart Jayne B. · CIK 0001519749 · Chief People Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 92,582

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001519749-21-000011 · edgardoc.xml · nonDerivative · entry 2

Hart Jayne B. · CIK 0001519749 · Chief People Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 88,807

F1 · kind: Represents the net exercise of outstanding stock options. The reporting person received 8,745 shares of common stock on net exercise of options to purchase 73,225 shares of common stock. The company withheld 64,480 shares of common stock for payment of the exercise price and tax withholdings, using the closing stock price on September 17, 2021 of $33.72.

SEC source: 0001519749-21-000011 · edgardoc.xml · nonDerivative · entry 1

Hart Jayne B. · CIK 0001519749 · Chief People Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 153,287

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001770252-21-000007 · edgardoc.xml · nonDerivative · entry 1

Lambert Nicole · CIK 0001770252 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 127,051

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

SEC source: 0001519749-21-000007 · edgardoc.xml · nonDerivative · entry 1

Hart Jayne B. · CIK 0001519749 · Chief People Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 80,062

F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on August 25, 2021.

SEC source: 0001770252-21-000005 · edgardoc.xml · nonDerivative · entry 1

Lambert Nicole · CIK 0001770252 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 127,996

F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on August 25, 2021.

SEC source: 0001219036-21-000025 · edgardoc.xml · nonDerivative · entry 1

LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 230,317

F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on August 25, 2021.

SEC source: 0001517026-21-000003 · edgardoc.xml · nonDerivative · entry 1

Verratti Mark · CIK 0001517026 · President, Myriad Neuroscience

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 156,048

F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on August 25, 2021.

SEC source: 0001621899-21-000007 · edgardoc.xml · nonDerivative · entry 2

Riggsbee Richard Bryan · CIK 0001621899 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 318,634

F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on August 25, 2021.

SEC source: 0001219036-21-000024 · edgardoc.xml · derivative · entry 9

LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 30,000 shares

Expires 2022-09-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F2 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable.

SEC source: 0001219036-21-000024 · edgardoc.xml · nonDerivative · entry 6

LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 232,550

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

SEC source: 0001219036-21-000024 · edgardoc.xml · nonDerivative · entry 5

LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 262,550

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

SEC source: 0001219036-21-000024 · edgardoc.xml · derivative · entry 8

LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 40,000 shares

Expires 2022-09-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F2 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable.

SEC source: 0001219036-21-000024 · edgardoc.xml · derivative · entry 7

LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,000

Underlying: Common Stock · 10,000 shares

Expires 2022-09-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F2 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable.

SEC source: 0001219036-21-000024 · edgardoc.xml · nonDerivative · entry 4

LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 232,550

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

SEC source: 0001219036-21-000024 · edgardoc.xml · nonDerivative · entry 3

LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 272,550

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

SEC source: 0001219036-21-000024 · edgardoc.xml · nonDerivative · entry 2

LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 232,550

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

SEC source: 0001219036-21-000024 · edgardoc.xml · nonDerivative · entry 1

LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 242,550

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

SEC source: 0000899243-21-033156 · doc4.xml · nonDerivative · entry 1

DIAZ PAUL J · CIK 0001194247 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 400,049

F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on August 13, 2021.

SEC source: 0001621899-21-000007 · edgardoc.xml · nonDerivative · entry 1

Riggsbee Richard Bryan · CIK 0001621899 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 321,692

SEC source: 0001219036-21-000022 · edgardoc.xml · derivative · entry 3

LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 80,000

Underlying: Common Stock · 28,225 shares

Expires 2022-09-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F3 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable.

SEC source: 0001219036-21-000022 · edgardoc.xml · nonDerivative · entry 2

LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 232,550

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.57 to $35.60, inclusive. The Reporting Person undertakes to provide to Myriad Genetics, Inc., any security holder of Myriad Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001219036-21-000022 · edgardoc.xml · nonDerivative · entry 1

LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 260,775

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

SEC source: 0001471518-21-000002 · edgardoc.xml · derivative · entry 6

Phanstiel S. Louise · CIK 0001471518 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 30,000 shares

Expires 2021-12-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable.

SEC source: 0001471518-21-000002 · edgardoc.xml · derivative · entry 5

Phanstiel S. Louise · CIK 0001471518 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 30,000 shares

Expires 2021-12-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable.